Papers
Topics
Authors
Recent
Search
2000 character limit reached

Designing a Robust LLM-Based Evaluation System for Agentic AI in Drug Discovery Through Human Alignment

Published 21 Aug 2026 in cs.LG | (2608.21057v1)

Abstract: Agentic LLM systems are reshaping scientific workflows in chemistry and drug discovery, but evaluating their open-ended, tool-augmented outputs remains a fundamental bottleneck. Reference-based metrics such as BLEU and ROUGE fail to capture semantic correctness, while expert human evaluation does not scale to the iteration speed these systems demand. The LLM-as-a-Judge paradigm has emerged as a scalable alternative, but existing drug discovery benchmarks deploy LLM judges without validating their alignment with human experts. In this work, we present an LLM-as-a-Judge evaluation framework for ChatInvent, an agentic drug discovery assistant deployed at AstraZeneca, with four contributions. First, we define four output-quality evaluation dimensions---Completeness, Relevancy, Structural Clarity, and Scope Adherence---alongside deterministic Tool Call Correctness checks. Second, we validate the judge through a human alignment study with five expert annotators, comparing Gemini 3.1 Pro, Claude Opus 4.7, GPT-5, and Llama 3.1 70B as candidate judges. Third, we optimize the best-performing judge using few-shot demonstrations of human-annotated examples, improving alignment with the human majority vote from 0.80 to 0.86. Fourth, applying the optimized judge to 70 held-out questions, we surface concrete limitations and find that informal phrasings do not systematically degrade output quality; if anything, it is helpful to have the LLM rewrite the original question before querying the agent. Our framework provides a reusable template for human-aligned evaluation of agentic systems in scientific domains.

Summary

No one has generated a summary of this paper yet.

Paper to Video (Beta)

No one has generated a video about this paper yet.

Whiteboard

No one has generated a whiteboard explanation for this paper yet.

Continue Learning

We haven't generated follow-up questions for this paper yet.

Tweets

Sign up for free to view the 2 tweets with 40 likes about this paper.